VERA Vera Therapeutics Inc.

15.84
+1.59  (+11%)
Previous Close 14.25
Open 15.33
52 Week Low 11.3
52 Week High 26.97
Market Cap $324,392,270
Shares 20,479,310
Float 10,213,263
Enterprise Value $234,901,477
Volume 21,703
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Atacicept (ORIGIN)
IgA Nephropathy
Phase 2b
Phase 2b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Atacicept
Lupus nephritis (LN)
Phase 2/3
Phase 2/3
Phase 2/3 trial to be initiated in 2022.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.

    Presentation details:

    Date:Friday, June 4, 2021
    Time:9:00 AM PT (12:00 PM ET)
    Presenter:Marshall Fordyce, MD, CEO and Founder of Vera

    A live webcast of the presentation can be accessed by visiting the investor relations section of the Company's website, www.veratx.com. A replay of the webcast…

    SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.

    Presentation details:

    Date:Friday, June 4, 2021
    Time:9:00 AM PT (12:00 PM ET)
    Presenter:Marshall Fordyce, MD, CEO and Founder of Vera

    A live webcast of the presentation can be accessed by visiting the investor relations section of the Company's website, www.veratx.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation date.

    About Vera Therapeutics

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera's lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept's reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). For more information please visit www.veratx.com.

    Investor Contact:

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

     



    Primary Logo

    View Full Article Hide Full Article
View All Vera Therapeutics Inc. News